Humana stock analysis (HUM)

UBS cut its PT to $250 from $380 following a significant selloff due to a drop in Medicare Advantage quality ratings.

HUM shares have taken a significant hit, dropping nearly 20% due to a sharp decline in Medicare Advantage plan ratings. The downgrade of its largest plan from 4.5 stars to 3.5 stars is a major factor, impacting future revenue projections. This sector, once a favorite among healthcare investors, is facing increased challenges.